BIRC5 and metastatic melanoma: Based on the findings from the initial studies [151, 152], vaccination of 3 modified cocktail peptides [FTELTLGEF (HLA-A1), LMLGEFLKL (HLA-A2) and EPDLAQCFY (HLA-B35) using 3 vaccination regimens against survivin in 61 HLA-A1/-A2/-B35-positive patients with treatment-refractory stage-IV metastatic melanoma were conducted in a Phase II trial; 55 patients were evaluable for response and survival, and 41/55 for survivin-specific T-cell reactivity (SSTR).